Clinical Trial Update: Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating whether HLA-B*5701 genetic screening can predict hypersensitivity to abacavir in HIV-infected individuals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Ziagen (Abacavir)

Snippet

Sponsor: GlaxoSmithKline | Conditions: HIV Infection | Phase 4 | Status: COMPLETED